Vaccine refers to biological products made of various pathogenic microorganisms for preventive inoculation. Among them, vaccines made of bacteria or spirochetes are also called vaccines. Vaccines are divided into live vaccines and dead vaccines. Commonly used live vaccines include BCG, polio vaccine, measles vaccine and plague vaccine.

Fubitai is a vaccine jointly produced by China and Shanghai Mainz. Fubitai is an mRNA COVID-19 vaccine. MRNA is a naturally occurring molecule with the blueprint of human cells, which can produce target proteins or immunogens, activate immune responses in vivo and fight against various pathogens. The mRNA vaccine uses the gene sequence of the virus rather than the virus itself, so the mRNA vaccine has no virus components.

Fubitai vaccine is an mRNA COVID-19 vaccine jointly developed by China Fosun Pharma and BioNTech. Fosun Pharma (600 196) said that the examination and approval of the mRNA COVID-19 vaccine "Fubitai" in the State Administration of Pharmaceutical Products has been basically completed, passed by experts, and the administrative examination and approval stage is being stepped up.

As of June 5438+ 10, 2022, Fubitai Xinguan vaccine has not been listed in China, but it has been listed in Hong Kong and other places, and local citizens can make an appointment to vaccinate. The most common adverse reactions are fever, redness, fever and pain at the inoculation site, which are generally relieved within 2 ~ 3 days without special treatment.

According to media reports, Fubitai vaccine is an mRNA COVID-19 vaccine jointly developed by Fosun Pharma and BioNTech. It was approved for emergency use in Hongkong, China, and special import approval by the Health Bureau in Macau, China. It can be seen that Fubitai vaccine should not be Pfizer vaccine. Fosun Pharma and Biotechnology have started production preparations ahead of schedule. Once the vaccine is approved, it can be supplied to China as soon as possible.